Ubiquitin-modifying enzymes in Huntington's disease
- PMID: 36926679
- PMCID: PMC10013475
- DOI: 10.3389/fmolb.2023.1107323
Ubiquitin-modifying enzymes in Huntington's disease
Abstract
Huntington's disease (HD) is a neurodegenerative disorder caused by a CAG repeat expansion in the N-terminus of the HTT gene. The CAG repeat expansion translates into a polyglutamine expansion in the mutant HTT (mHTT) protein, resulting in intracellular aggregation and neurotoxicity. Lowering the mHTT protein by reducing synthesis or improving degradation would delay or prevent the onset of HD, and the ubiquitin-proteasome system (UPS) could be an important pathway to clear the mHTT proteins prior to aggregation. The UPS is not impaired in HD, and proteasomes can degrade mHTT entirely when HTT is targeted for degradation. However, the mHTT protein is differently ubiquitinated when compared to wild-type HTT (wtHTT), suggesting that the polyQ expansion affects interaction with (de) ubiquitinating enzymes and subsequent targeting for degradation. The soluble mHTT protein is associated with several ubiquitin-modifying enzymes, and various ubiquitin-modifying enzymes have been identified that are linked to Huntington's disease, either by improving mHTT turnover or affecting overall homeostasis. Here we describe their potential mechanism of action toward improved mHTT targeting towards the proteostasis machinery.
Keywords: Huntington’s disease; deubiquitinating enzyme; huntingtin; ligase; neurodegenerative disease; proteasome; proteostasis; ubiquitin.
Copyright © 2023 Sap, Geijtenbeek, Schipper-Krom, Guler and Reits.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures
References
-
- Aladdin A., Király R., Boto P., Regdon Z., Tar K. (2019). Juvenile huntington’s disease skin fibroblasts respond with elevated parkin level and increased proteasome activity as a potential mechanism to counterbalance the pathological consequences of mutant huntingtin protein. Int. J. Mol. Sci. 20 (21), 5338. 10.3390/ijms20215338 - DOI - PMC - PubMed
Publication types
LinkOut - more resources
Full Text Sources
